ID   CTV-1
AC   CVCL_1150
SY   CTV1
DR   CLO; CLO_0002638
DR   CLDB; cl927
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473579
DR   CCLE; CTV1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM00951
DR   ChEMBL-Cells; CHEMBL3308189
DR   ChEMBL-Targets; CHEMBL2366360
DR   Cosmic; 717685
DR   Cosmic; 753548
DR   Cosmic; 787426
DR   Cosmic; 947372
DR   Cosmic; 975244
DR   Cosmic; 998755
DR   Cosmic; 1078737
DR   Cosmic; 1151776
DR   Cosmic; 1524794
DR   Cosmic; 1760520
DR   Cosmic; 2089657
DR   Cosmic; 2131536
DR   Cosmic; 2306203
DR   Cosmic-CLP; 753548
DR   DepMap; ACH-002222
DR   DSMZ; ACC-40
DR   GDSC; 753548
DR   GEO; GSM1374458
DR   GEO; GSM1669712
DR   LINCS_LDP; LCL-1013
DR   PharmacoDB; CTV1_268_2019
DR   Wikidata; Q54814774
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3458274;
RX   PubMed=6593267;
RX   PubMed=9379676;
RX   PubMed=15843827;
RX   PubMed=20164919;
RX   PubMed=22675565;
RX   PubMed=23955599;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Problematic cell line: Probably misidentified. Originally thought to be a acute monoblastic leukemia but seems to be a T-ALL cell line (PubMed=15843827). Was also said to originate from a 40 year old female patient (PubMed=6593267) but has a male STR profile.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: ~36 hours (PubMed=6593267); ~40 hours (DSMZ).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: Heterozygous for FBXW7 p.Gly477Ser (c.1429G>A) and p.Arg505Cys (c.1513C>T) (ClinVar=VCV000069961) (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Heterozygous for FLT3 p.Gly831Glu (c.2492G>A) (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Heterozygous for LCK p.Ala353Val (c.1058C>T), p.Pro447Leu (c.1340C>T) and p.Ala500Thr (c.1498G>A) (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Heterozygous for NF1 p.Gly1532Arg (c.4594G>A) (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Heterozygous for NOTCH1 p.Ser2523Ter (c.7568C>A) (Cosmic-CLP).
CC   Sequence variation: Heterozygous for PDGFRB p.Met772Ile (c.2316G>A) (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Heterozygous for RET p.Cys656Phe (c.1967G>T) (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Heterozygous for STK11 p.Arg75Met (c.224G>T) and p.Lys175Met (c.524A>T) (PubMed=22675565; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.02%; Native American=1.28%; East Asian, North=0%; East Asian, South=0.34%; South Asian=5.64%; European, North=45.18%; European, South=46.55% (PubMed=30894373).
CC   Misspelling: CTY-1; In Cosmic 717685 and PubMed=9379676.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 9,12
ST   D13S317: 11,12
ST   D16S539: 9,14
ST   D5S818: 12
ST   D7S820: 11,13
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 18,19 (Cosmic-CLP)
ST   vWA: 17,18 (DSMZ)
DI   NCIt; C9142; Adult T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_RX77 ! CTV-2
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 28
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3458274;
RA   Drexler H.G., Gaedicke G., Maeda S., Chen P.-M., Minowada J.;
RT   "Monocytoid leukemia cell line CTV-1: morphological, immunological and
RT   isoenzymatic characteristics.";
RL   Tumor Biol. 6:503-517(1986).
//
RX   PubMed=6593267; DOI=10.20772/cancersci1959.75.8_660;
RA   Chen P.-M., Chiu C.-F., Chiou T.-J., Maeda S., Chiang H., Tzeng C.-H.,
RA   Sugiyama T., Chiang B.-N.;
RT   "Establishment and characterization of a human monocytoid leukemia
RT   cell line, CTV-1.";
RL   Gann 75:660-664(1984).
//
RX   PubMed=9379676; DOI=10.1016/S0145-2126(97)00036-2;
RA   Sheng X.-M., Kawamura M., Ohnishi H., Ida K., Hanada R., Kojima S.,
RA   Kobayashi M., Bessho F., Yanagisawa M., Hayashi Y.;
RT   "Mutations of the RAS genes in childhood acute myeloid leukemia,
RT   myelodysplastic syndrome and juvenile chronic myelocytic leukemia.";
RL   Leuk. Res. 21:697-701(1997).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22675565; DOI=10.1371/journal.pone.0038463;
RA   Kalender Atak Z., De Keersmaecker K., Gianfelici V., Geerdens E.,
RA   Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G.,
RA   Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P.,
RA   Cools J., Aerts S.;
RT   "High accuracy mutation detection in leukemia on a selected panel of
RT   cancer genes.";
RL   PLoS ONE 7:E38463-E38463(2012).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//